These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 7554037

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R.
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [Abstract] [Full Text] [Related]

  • 3. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
    Sasaki Y, Mizuno S, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K, Sekine I, Miyata Y, Saijo N.
    Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
    Sloan JA, Atherton P, Reid J, Pitot HC, Erlichman C, Schaaf L.
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):241-9. PubMed ID: 11592347
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
    Catimel G, Chabot GG, Guastalla JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boué A, Mahjoubi M, Clavel M.
    Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
    Sasaki Y, Yoshida Y, Sudoh K, Hakusui H, Fujii H, Ohtsu T, Wakita H, Igarashi T, Itoh K.
    Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.
    Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A.
    J Clin Oncol; 1996 Oct; 14(10):2688-95. PubMed ID: 8874328
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients.
    Barilero I, Gandia D, Armand JP, Mathieu-Boué A, Ré M, Gouyette A, Chabot GG.
    J Chromatogr; 1992 Mar 27; 575(2):275-80. PubMed ID: 1629304
    [Abstract] [Full Text] [Related]

  • 13. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
    Mathijssen RH, van Alphen RJ, de Jonge MJ, Verweij J, de Bruijn P, Loos WJ, Nooter K, Vernillet L, Stoter G, Sparreboom A.
    Anticancer Drugs; 1999 Jan 27; 10(1):9-16. PubMed ID: 10194542
    [Abstract] [Full Text] [Related]

  • 14. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies.
    Escoriaza J, Aldaz A, Castellanos C, Calvo E, Giráldez J.
    J Chromatogr B Biomed Sci Appl; 2000 Apr 14; 740(2):159-68. PubMed ID: 10821401
    [Abstract] [Full Text] [Related]

  • 15. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.
    Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Yamakido M.
    Cancer Chemother Pharmacol; 1997 Apr 14; 40(5):449-52. PubMed ID: 9272124
    [Abstract] [Full Text] [Related]

  • 16. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM.
    Cancer Chemother Pharmacol; 1998 Apr 14; 41(6):464-8. PubMed ID: 9554590
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of CPT-11 in rhesus monkeys.
    Inaba M, Ohnishi Y, Ishii H, Tanioka Y, Yoshida Y, Sudoh K, Hakusui H, Mizuno N, Ito K, Sugiyama Y.
    Cancer Chemother Pharmacol; 1998 Apr 14; 41(2):103-8. PubMed ID: 9443622
    [Abstract] [Full Text] [Related]

  • 18. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC, Vrignaud P, Lavelle F, Chabot GG.
    Anticancer Drugs; 1996 Jun 14; 7(4):437-60. PubMed ID: 8826613
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
    Rothenberg ML, Kuhn JG, Schaaf LJ, Rodriguez GI, Eckhardt SG, Villalona-Calero MA, Rinaldi DA, Hammond LA, Hodges S, Sharma A, Elfring GL, Petit RG, Locker PK, Miller LL, von Hoff DD.
    Ann Oncol; 2001 Nov 14; 12(11):1631-41. PubMed ID: 11822765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.